NextFin News - Cardinal Health shares have entered a period of significant valuation compression following a third-quarter earnings report that, while beating profit expectations, triggered a sharp sell-off due to a revenue miss and a sizable impairment charge. The Dublin, Ohio-based pharmaceutical distributor saw its stock price retreat to approximately $199 on Monday, a level that has prompted Jim Cramer’s Charitable Trust to increase its stake by 50 shares. This move raises the trust’s total holding to 525 shares, boosting the position’s portfolio weighting to 2.75%.
The market’s reaction centers on a complex set of results for the period ended March 31, 2026. Cardinal Health reported revenue of $60.9 billion, an 11% year-over-year increase driven by robust demand for branded specialty pharmaceuticals and GLP-1 medications. However, this figure fell slightly short of analyst projections. More critically, the company recorded a $184 million pre-tax goodwill impairment charge related to its Navista and ION reporting units. Management attributed the write-down to changes in the risk profile of business plans, which necessitated a higher discount rate in their valuation models.
Jeff Marks, Director of Portfolio Management for the CNBC Investing Club, characterized the recent price action as an opportunity to acquire a high-quality compounder at a discount. Marks, who works closely with Jim Cramer, typically favors companies with strong cash flow and clear earnings visibility. His decision to add to the position reflects a belief that the market has overemphasized the non-cash impairment charge while overlooking a significant upward revision in future earnings potential. According to FactSet data, the consensus estimate for Cardinal’s fiscal 2027 earnings per share has actually risen to $11.91, up from $11.60 prior to the report.
This bullish stance is not yet a universal consensus on Wall Street. While the Investing Club points to a forward price-to-earnings multiple of 16.5 times—down from 20 times in early March—some analysts remain cautious regarding the company’s Medical segment margins. The impairment in the Navista oncology unit suggests that the integration of recent acquisitions and the pivot toward higher-margin services may be facing more friction than initially anticipated. Skeptics argue that until the Medical segment demonstrates consistent operational leverage, the stock may struggle to reclaim its March highs near $229.
Despite these headwinds, the core pharmaceutical distribution business remains a powerhouse of cash generation. The company ended the quarter with $3.9 billion in cash and equivalents, bolstered by the completion of its $1.9 billion acquisition of Solaris Health. This capital strength allows for continued share repurchases and dividend growth, which management expects will contribute to low-to-mid teens earnings growth over the long term. The current valuation suggests that investors are paying a significantly lower premium for this growth than they were just eight weeks ago.
The divergence between the falling share price and rising earnings estimates creates a classic valuation gap that active managers often seek to exploit. For the Charitable Trust, the thesis rests on the sustainability of the generics program and the continued tailwinds from specialty drug volumes. While the revenue miss and the Navista write-down provided the catalyst for the recent 12% decline from peak levels, the underlying trajectory of the business appears to have remained intact for those willing to look past the quarterly noise.
Explore more exclusive insights at nextfin.ai.
